Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris

Ital J Dermatol Venerol. 2021 Aug;156(4):501-502. doi: 10.23736/S2784-8671.20.06743-7. Epub 2020 Nov 12.

Authors

Manuela Papini¹, Ada Russo², Ylenia Natalini², Lucas Troiani², Lorenzo Cassiani²

Affiliations

¹ Dermatology Clinic of Terni, University of Perugia, Terni, Italy - manuela.papini@unipg.it.
² Dermatology Clinic of Terni, University of Perugia, Terni, Italy.

PMID: 33179881
DOI: 10.23736/S2784-8671.20.06743-7

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Pityriasis Rubra Pilaris* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
secukinumab